Señales en vivo de SILO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	14 087.00
Volumen promedio	203 501
Capitalización de mercado	5.26M
EPS	$0 ( 2024-03-25 )
Próxima fecha de ganancias	( $0 ) 2024-06-24
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.570
ATR14	$0.0270 (1.46%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Weisblum Eric	Buy	400	Common Stock
2024-04-04	Weisblum Eric	Buy	600	Common Stock
2024-04-01	Weisblum Eric	Buy	1 100	Common Stock
2024-03-28	Weisblum Eric	Buy	3 408	Common Stock
2023-12-20	Weisblum Eric	Buy	200	Common Stock

INSIDER POWER
100.00
Last 55 transactions
Buy: 22 165 052 \| Sell: 3 696 660

Silo Pharma, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Silo Pharma, Inc. Finanzas

Annual	2023
Ingresos:	$72 102.00
Beneficio Bruto:	$-805 361 (-1 116.97 %)
EPS:	$-1.200

FY	2023
Ingresos:	$72 102.00
Beneficio Bruto:	$-805 361 (-1 116.97 %)
EPS:	$-1.200

FY	2022
Ingresos:	$72 102.00
Beneficio Bruto:	$66 264.00 (91.90 %)
EPS:	$-1.710

FY	2021
Ingresos:	$71 264.00
Beneficio Bruto:	$66 260.00 (92.98 %)
EPS:	$2.00

Financial Reports:

No articles found.

Silo Pharma, Inc.

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research for patients with depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland, The Regents of the University of California, and Columbia University. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.